Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c01627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Lennart Brewitz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield …. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, Nitriles, SARS-CoV-2. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Biotechnology and Biological Sciences Research Council, Wellcome Trust.
Abstract (Originalsprache)
Nirmatrelvir (PF-07321332) is a nitrile-bearing small-molecule inhibitor that, in combination with ritonavir, is used to treat infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Nirmatrelvir interrupts the viral life cycle by inhibiting the SARS-CoV-2 main protease (Mpro), which is essential for processing viral polyproteins into functional nonstructural proteins. We report studies which reveal that derivatives of nirmatrelvir and other Mpro inhibitors with a nonactivated terminal alkyne group positioned similarly to the electrophilic nitrile of nirmatrelvir can efficiently inhibit isolated Mpro and SARS-CoV-2 replication in cells. Mass spectrometric and crystallographic evidence shows that the alkyne derivatives inhibit Mpro by apparent irreversible covalent reactions with the active site cysteine (Cys145), while the analogous nitriles react reversibly. The results highlight the potential for irreversible covalent inhibition of Mpro and other nucleophilic cysteine proteases by alkynes, which, in contrast to nitriles, can be functionalized at their terminal position to optimize inhibition and selectivity, as well as pharmacodynamic and pharmacokinetic properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield Road, Oxford OX1 3TA, United Kingdom.
- Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot OX11 0DE, United Kingdom.
- Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom.
- Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, United Kingdom.
ORCID-Profile: Lennart Brewitz, C David Owen, Tika R Malla, Adam D Crawshaw, Anna J Warren, Martin A Walsh, Christopher J Schofield
Förderung
- Cancer Research UK
- Biotechnology and Biological Sciences Research Council
- Wellcome Trust
- Oak Foundation
- University of Oxford
- King Abdulaziz University
Zitieren
APA
Brewitz, L., Dumjahn, L., Zhao, Y., Owen, C. D., Laidlaw, S. M., Malla, T. R., Nguyen, D., Lukacik, P., Salah, E., Crawshaw, A. D., Warren, A. J., Trincao, J., Strain-Damerell, C., Carroll, M. W., Walsh, M. A., & Schofield, C. J. (2023). Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01627
Vancouver
Brewitz L, Dumjahn L, Zhao Y, Owen CD, Laidlaw SM, Malla TR, et al. Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01627
BibTeX
@article{Brewitz2023,
author = {Brewitz, Lennart and Dumjahn, Leo and Zhao, Yilin and Owen, C David and Laidlaw, Stephen M and Malla, Tika R and Nguyen, Dung and Lukacik, Petra and Salah, Eidarus and Crawshaw, Adam D and Warren, Anna J and Trincao, Jose and Strain-Damerell, Claire and Carroll, Miles W and Walsh, Martin A and Schofield, Christopher J},
title = {Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c01627}
}
EUVIMED